National Cancer Institute (NCI): Oligodendroglioma trials

The registry lists 44 Oligodendroglioma studies with National Cancer Institute (NCI) as lead sponsor. 0 are open to participants now and 18 have results posted.

Phase 1 28Phase 2 19No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Protein Phosphatase 2A Inhibitor, in Recurrent GlioblastomaCompletedNCT03027388Phase 2Results posted
• Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma MultiformeCompletedNCT01648348Phase 1/2Results posted
• Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain TumorsCompletedNCT01609790Phase 2Results posted
• Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or EpendymomaCompletedNCT01462695Phase 2Results posted
• RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant GliomaTerminatedNCT01189240Phase 1/2Results posted
• Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant GliomaCompletedNCT01051557Phase 1/2Results posted
• A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade GliomasCompletedNCT00995007Phase 2Results posted
• Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard TherapyCompletedNCT00679354Phase 2Results posted
• Tandutinib Plus Bevacizumab to Treat Recurrent Brain TumorsCompletedNCT00667394Phase 2Results posted
• Sunitinib in Treating Patients With Recurrent Malignant GliomasCompletedNCT00499473Phase 2Results posted
• Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck CancerCompletedNCT00492089Phase 2Results posted
• Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade GliomaCompletedNCT00381797Phase 2Results posted
• VEGF Trap in Treating Patients With Recurrent Malignant Gliomas That Did Not Respond to TemozolomideCompletedNCT00369590Phase 2Results posted
• Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant GliomaCompletedNCT00112736Phase 1/2Results posted
• Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System TumorsCompletedNCT00095940Phase 1/2Results posted
• FR901228 in Treating Patients With Recurrent High-Grade GliomasCompletedNCT00085540Phase 1/2Results posted
• Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive MeningiomaCompletedNCT00045110Phase 1/2Results posted
• Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed GliomasCompletedNCT00042991Phase 1/2Results posted
• Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade GliomaCompletedNCT02101905Phase 1
• High-Dose Vorinostat and Fractionated Stereotactic Body Radiation Therapy in Treating Patients With Recurrent GliomaTerminatedNCT01378481Phase 1
• AZD8055 for Adults With Recurrent GliomasCompletedNCT01316809Phase 1
• (11C)dLop as a Marker of P-Glycoprotein Function in Patients With GliomasTerminatedNCT01281982
• RO4929097 in Treating Patients With Recurrent Invasive GliomasTerminatedNCT01269411Phase 1
• Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid TumorsCompletedNCT01131234Phase 1
• RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant GliomaCompletedNCT01119599Phase 1
• Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell LeukemiaTerminatedNCT01088763Phase 1
• Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord TumorsCompletedNCT01076530Phase 1
• Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and LymphomaCompletedNCT00994500Phase 1
• ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS TumorsCompletedNCT00946335Phase 1
• Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant GliomaCompletedNCT00650923Phase 1
• Use of EF5 to Measure the Oxygen Level in Tumor Cells of Patients Undergoing Surgery or Biopsy for Newly Diagnosed Supratentorial Malignant GliomaTerminatedNCT00430079Not applicable
• AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS TumorsCompletedNCT00326664Phase 1
• Vorinostat and Temozolomide in Treating Patients With Malignant GliomasActive, not recruitingNCT00268385Phase 1
• Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain TumorsTerminatedNCT00110032Phase 1
• Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS TumorsCompletedNCT00100880Phase 1
• Sorafenib in Treating Patients With Recurrent or Progressive Malignant GliomaCompletedNCT00093613Phase 1
• Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem GliomaCompletedNCT00070525Phase 2
• Cilengitide in Treating Children With Refractory Primary Brain TumorsCompletedNCT00063973Phase 1
• Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain TumorsCompletedNCT00052780Phase 1
• Eligibility Screening of Patients With Central Nervous System Tumors for the National Cancer Institute s (NCI) Clinical Research ProtocolsTerminatedNCT00035373
• Genetic Analysis of Brain TumorsTerminatedNCT00031538
• Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney DysfunctionCompletedNCT00030498Phase 1
• Natural History of Patients With Brain and Spinal Cord TumorsCompletedNCT00009035
• Bortezomib in Treating Patients With Recurrent GliomaTerminatedNCT00006773Phase 1